Anti-EGFR therapy in head and neck squamous cell carcinoma can initiate adaptive immune response by promoting NK cells mediated significantly higher HLA-DR expression on DC to present tumor antigens to CD8+T cells [43]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.